Mycenax Biotech Inc. (TPEX:4726)

Mycenax Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	269.57	519.27	1,323	286.93	291.14
Short-Term Investments	7.3	148.42	16.12	-	-
Cash & Short-Term Investments	276.87	667.69	1,339	286.93	291.14
Cash Growth	-58.53%	-50.15%	366.84%	-1.45%	5.02%
Accounts Receivable	140.74	58.53	81.32	320.84	169.03
Other Receivables	7.73	4.69	3.09	11.33	5.51
Receivables	148.47	63.22	84.41	332.17	174.54
Inventory	64.94	112.33	246.72	173.3	84.85
Prepaid Expenses	71.45	83.25	103.22	89.28	23.82
Other Current Assets	174.66	171.53	149.95	15.73	2.16
Total Current Assets	736.38	1,098	1,924	897.41	576.51
Property, Plant & Equipment	1,705	1,847	1,978	1,351	786.73
Long-Term Investments	177.87	190.81	199.51	109.59	191.81
Goodwill	23.92	23.92	23.92	23.92	23.92
Other Intangible Assets	12.34	18.98	25.93	33.71	36.72
Long-Term Deferred Tax Assets	98.6	95.49	89.72	81.11	83.45
Other Long-Term Assets	614.67	495.85	211.93	642.46	53.41
Total Assets	3,368	3,770	4,453	3,139	1,753
Accounts Payable	34.63	44.05	52.52	54.68	40.31
Accrued Expenses	98.05	112.32	104.21	96.4	66.6
Short-Term Debt	-	-	100	50	100
Current Portion of Long-Term Debt	168.08	125.92	105.88	15.6	-
Current Portion of Leases	31.92	30.57	37.28	28.59	24.33
Current Income Taxes Payable	-	-	-	-	0.65
Current Unearned Revenue	230.85	187.28	142.28	152.12	125.9
Other Current Liabilities	97.97	253.28	92.57	142.69	66.99
Total Current Liabilities	661.5	753.42	634.73	540.07	424.78
Long-Term Debt	611.37	530.4	656.32	474.4	-
Long-Term Leases	72.04	39.39	56.37	176.06	72.28
Long-Term Deferred Tax Liabilities	-	-	-	3.75	6.68
Other Long-Term Liabilities	-	-	-	38.07	37.14
Total Liabilities	1,345	1,323	1,347	1,232	540.89
Common Stock	2,070	2,059	2,053	1,533	1,282
Additional Paid-In Capital	421.11	1,074	1,468	576.95	53.11
Retained Earnings	-466.91	-682.64	-406.83	-254.34	-207.23
Comprehensive Income & Other	-0.79	-3.32	-8.8	50.72	83.41
Shareholders' Equity	2,023	2,447	3,106	1,907	1,212
Total Liabilities & Equity	3,368	3,770	4,453	3,139	1,753
Total Debt	883.39	726.28	955.85	744.64	196.61
Net Cash (Debt)	-606.53	-58.59	383.63	-457.72	94.53
Net Cash Growth	-	-	-	-	-58.98%
Net Cash Per Share	-2.94	-0.29	2.32	-3.08	0.73
Filing Date Shares Outstanding	207.01	205.89	205.31	153.33	128.24
Total Common Shares Outstanding	207.01	205.89	205.31	153.33	128.24
Working Capital	74.89	344.59	1,289	357.34	151.73
Book Value Per Share	9.77	11.89	15.13	12.43	9.45
Tangible Book Value	1,987	2,404	3,056	1,849	1,151
Tangible Book Value Per Share	9.60	11.68	14.88	12.06	8.98
Buildings	792.86	792.86	791.68	-	-
Machinery	1,594	1,603	1,575	837.57	688.02
Construction In Progress	158.09	106.85	3.35	624.35	260.37
Leasehold Improvements	325.53	317.34	307.77	276.23	246.21

Updated Mar 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.